{"id":36600,"date":"2025-07-03T17:08:16","date_gmt":"2025-07-03T09:08:16","guid":{"rendered":"https:\/\/flcube.com\/?p=36600"},"modified":"2025-07-03T17:08:17","modified_gmt":"2025-07-03T09:08:17","slug":"shanghai-henlius-biotech-earns-gmp-certification-for-prolia-xgeva-biosimilar-hlx14-and-perjeta-biosimilar-hlx11","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36600","title":{"rendered":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11"},"content":{"rendered":"\n

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696<\/a>) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company’s global expansion and quality assurance.<\/p>\n\n\n\n

Biosimilars Developed to Meet Global Standards<\/strong>
Both biosimilars were developed in compliance with the regulatory requirements of China, the EU, and the US. HLX14 is under regulatory review in the EU, US, and Canada for treating osteoporosis in postmenopausal women at high fracture risk. HLX11 is awaiting decisions in China, the EU, US, and Canada for use in combination with trastuzumab and chemotherapy as a neoadjuvant treatment for HER2-positive early\/locally advanced\/inflammatory breast cancer.<\/p>\n\n\n\n

Commercialization Partnership with Organon<\/strong>
Henlius Biotech has out-licensed both products to Organon LLC for commercialization outside China. This partnership covers major markets including the US, EU, and Canada. The GMP certification from Belgium’s FAMHP further solidifies Henlius Biotech’s position in the global biosimilars market and its commitment to providing high-quality therapeutic options to patients worldwide.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice…<\/p>\n","protected":false},"author":1,"featured_media":36603,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,43,16,270,862,174,163],"class_list":["post-36600","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-biosimilars","tag-cancer","tag-henlius-biotech","tag-hkg-2696","tag-organon","tag-roche"],"yoast_head":"\nShanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36600\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11\" \/>\n<meta property=\"og:description\" content=\"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36600\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-03T09:08:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-03T09:08:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Henlius Biotech Earns GMP Certification for Prolia\\\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11\",\"datePublished\":\"2025-07-03T09:08:16+00:00\",\"dateModified\":\"2025-07-03T09:08:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0313.webp\",\"keywords\":[\"Amgen\",\"Biosimilars\",\"Cancer\",\"Henlius Biotech\",\"HKG: 2696\",\"Organon\",\"Roche\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36600#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36600\",\"name\":\"Shanghai Henlius Biotech Earns GMP Certification for Prolia\\\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0313.webp\",\"datePublished\":\"2025-07-03T09:08:16+00:00\",\"dateModified\":\"2025-07-03T09:08:17+00:00\",\"description\":\"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\\\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36600\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0313.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0313.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Henlius Biotech Earns GMP Certification for Prolia\\\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36600#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Henlius Biotech Earns GMP Certification for Prolia\\\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11 - Insight, China's Pharmaceutical Industry","description":"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36600","og_locale":"en_US","og_type":"article","og_title":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11","og_description":"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.","og_url":"https:\/\/flcube.com\/?p=36600","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-03T09:08:16+00:00","article_modified_time":"2025-07-03T09:08:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36600#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36600"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11","datePublished":"2025-07-03T09:08:16+00:00","dateModified":"2025-07-03T09:08:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36600"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36600#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","keywords":["Amgen","Biosimilars","Cancer","Henlius Biotech","HKG: 2696","Organon","Roche"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36600#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36600","url":"https:\/\/flcube.com\/?p=36600","name":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36600#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36600#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","datePublished":"2025-07-03T09:08:16+00:00","dateModified":"2025-07-03T09:08:17+00:00","description":"China's Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice (GMP) certificates from Belgium's Federal Agency for Medicines and Health Products (FAMHP) for its production lines of HLX14, a biosimilar of Amgen\u2019s Prolia\/Xgeva (denosumab), and HLX11, a biosimilar of Roche\u2019s Perjeta (pertuzumab). This marks a significant milestone in the company's global expansion and quality assurance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36600#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36600"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36600#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","width":1080,"height":608,"caption":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36600#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Henlius Biotech Earns GMP Certification for Prolia\/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0313.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36600"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36600\/revisions"}],"predecessor-version":[{"id":36604,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36600\/revisions\/36604"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36603"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}